Longjin Pharmaceutical(SZ:002750)2022-12-06 02:40Group 1: Company Overview - Kunming Longjin Pharmaceutical Co., Ltd. is involved in the production of traditional Chinese medicine, specifically focusing on the extraction of active ingredients from the plant "Dengzhanhua" [1]. - The company has a GMP production line and showcases its production process and design advantages during investor visits [1]. Group 2: Market Position and Product Information - The market share of Dengzhanhua series preparations in the cardiovascular traditional Chinese medicine market is approximately 1.99%, with hospital coverage only at 15% to 20%, indicating significant growth potential despite a slowing growth rate [2]. - The purity of the active ingredient, baicalin, in the injectable Dengzhanhua product exceeds 98%, and its safety and efficacy have been widely validated [2]. Group 3: Shareholder Structure - The company has three major shareholders, with Qunxing Investment being the controlling shareholder, primarily investing in Longjin Pharmaceutical and establishing a Dengzhanhua planting base [2]. - The second-largest shareholder, Lixing Industrial, also invests in other pharmaceutical companies, while the third-largest shareholder, Huixinsheng Investment, is formed by company executives and their affiliates [2]. Group 4: Future Plans and Financial Management - The company plans to expand through mergers and acquisitions, focusing on the pharmaceutical industry and considering investments in OTC and health sectors [2]. - Idle funds are primarily used for purchasing bank principal-protected financial products, with financing needs dependent on potential investment projects [2].